Study Of Planiq Feasibility Dvh Usage To Improve Cervical Cancer Treatment Plan

The implementation of the optimal treatment plan by determining what is reasonably achievable is a challenge, influenced also by the planner's experience and available time. The aim of this study is to explore the clinical advantage of PlanIQ Feasibility DVH (FDVH) module in the design process of cervical cancer treatment plan. Tomotherapy clinically delivered treatment plans (CdP) of twenty cervical cancer patients randomly selected were included in this retrospective study. Using the same clinical dose prescriptions as CdP, an ideal plan (IP) was generated for each patient by PlanIQ FDVH using the minimal dose that any voxel outside the targets must receive given 100% target coverage. A new treatment plan (NP) was therefore optimized using as endpoint the ideal target dose distribution and organs-at-risk (OAR) dose limit determined by IP. Dose volume histogram dosimetric parameters D95, conformity and homogeneity index (HI, CI, respectively) for the target and the mean dose (Dm), V20 and V30 for the OARs were used to compare CdP and NP. Data were analyzed with the t-Student test; p-value less than 0.05 was considered statistically significant. The OARs and target mean dosimetric values obtained for CdP and NP were reported in Table 1. The results show that both plan groups achieve the clinical requirements. The target dosimetric parameters D95, CI, HI present no statistical differences; for the rectum, the bladder and the small intestine, Dm, V20 and V30 values were significant lower for the NP than for CdP (p < 0.05). Table 1: mean OARs and target DVH dosimetric parameters for CdP and NP, and corresponding p value results of t-Student test.Tabled 1Abstract 2622; TableCdPNPpPTVD9549.6±0.5149.58±0.570.53CI0.92±0.030.92±0.040.68HI0.05±0.040.04±0.040.89BladderDm25.53±4.6322.46±4.320.01V2092.60±3.5082.30±4.100.00V3053.80±4.6048.70±3.400.01RectumDm24.38±5.3221.54±4.640.01V2086.51±4.6078.60±3.700.01V3051.50±5.5044.60±4.210.00Small IntestineDm21.92±3.1419.65±2.850.01V2062.70±5.1056.40±4.600.00V3032.51±4.2128.31±3.300.01 Open table in a new tab PlanIQ FDVH provide clear limits for OARs dose assuring a clinical guidance in the design process of cervical cancer treatment plan.